Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Treatment of Tuberculosis | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Abstract The American Thoracic Society, Centers for Disease Control and Prevention, and
Infectious Diseases Society of America jointly sponsored the development of this guideline …

Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Background Multidrug-resistant tuberculosis had high treatment failure and mortality.
Success rate of treatment currently 56% at global level, 48% in Indonesia and 36% in West …

Model‐informed drug development (MIDD) has a long and rich history in infectious
diseases. This review describes foundational principles of translational anti‐infective …

Background Levofloxacin is used for the treatment of multidrug-resistant tuberculosis;
however the optimal dose is unknown. Methods We used the hollow fiber system model of …

Improved knowledge regarding the tissue penetration of antituberculosis drugs may help
optimize drug management. Patients with drug-resistant pulmonary tuberculosis undergoing …

Background In 2020, WHO guidelines prioritised the use of a standard fully oral short
treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin …